The advent of immuno-oncology (IO) drugs profoundly changes our understanding of cancer biology as well as the management of patients at bedside. This is especially true for melanoma, renal cell carcinoma, non-small cell lung cancer, head and neck squamous cell carcinoma, Hodgkin's lymphoma or bladder cancer, for which these drugs already demonstrated substantial improvements in the patients' outcome. Beyond these indications, objective tumour responses have been reported in more than 20 different cancer types in early phase trials.
from #AlexandrosSfakianakis via Alexandros G.Sfakianakis on Inoreader http://ift.tt/2nCduBJ
via IFTTT
Εγγραφή σε:
Σχόλια ανάρτησης (Atom)
Δημοφιλείς αναρτήσεις
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2Gchesc via IFTTT
-
Abstract Determining the cause of unexplained death in all age groups, including infants, is a priority in forensic medicine. The triple r...
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2BeOBVJ via IFTTT
-
from #Medicine-SfakianakisAlexandros via o.lakala70 on Inoreader https://ift.tt/2rxuJIO via IFTTT
-
Abstract In this paper we present the study of a skull belonging to a young male from the Italian Bronze Age showing three perimortem inju...
-
Find out more about the wide range of A Levels and full time courses available at Longley Park Sixth Form College, the only independent Sixt...
-
Abstract To measure integral doses in image-guided radiation therapy, we developed an integral condenser dosimeter comprising a disposable...
-
Objectives. To assess the association between short-term postoperative cognitive dysfuction (POCD) and inflammtory response in patients unde...
-
Abstract Layer-by-layer (LbL) dip coating, accompanying with the use of micelle structure, allows hydrophobic molecules to be coated on me...
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου